Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 9/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 7/20 | 1.00 |
| ▸ | KDM1A | O60341 | 14/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.95 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL7759844 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL6388781 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL56350 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL56351 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL56352 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL4380284 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL3406205 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL13764364 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL1649712 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL4740285 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235516-A1 | DEVELOPMENT OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS AS ANTI-CANCER REAGENTS | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2025-11-13 | — | — | WO | claimed |
| US-20240352422-A1 | DIRECT REPROGRAMMING OF CELLS INTO CARDIAC PURKINJE-LIKE CELLS USING A UNIVERSAL SMALLMOLECULE COCKTAIL | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-10-24 | — | — | US | claimed |
| WO-2023022892-A1 | DIRECT REPROGRAMMING OF CELLS INTO CARDIAC PURKINJE-LIKE CELLS USING A UNIVERSAL SMALLMOLECULE COCKTAIL | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-02-23 | — | — | WO | claimed |
| EP-3003301-A2 | NOVEL SUICIDAL LSD1 INHIBITORS TARGETING SOX2-EXPRESSING CANCER CELLS | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada (US) | 2016-04-13 | — | — | EP | claimed |
| WO-2014194280-A2 | NOVEL SUICIDAL LSD1 INHIBITORS TARGETING SOX2-EXPRESSING CANCER CELLS | The Board of Regents of the Nevada System of Higher Education on behalf of the University of (US) | 2014-12-04 | — | — | WO | claimed |
| US-20130143824-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-20120058953-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110039324-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2011-02-17 | — | — | US | claimed |
| US-20090148921-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. (US) | 2009-06-11 | — | — | US | claimed |
| EP-1590666-B1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2008-07-09 | — | — | EP | claimed |
| EP-1590666-A4 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1590666-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | Genentech, Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040171554-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004072641-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2004-08-26 | — | — | WO | claimed |
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | claimed |
| US-5340838-A | Administering serotonin agonist to mammals | ELI LILLY AND COMPANY (US) | 1994-08-23 | — | — | US | claimed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | claimed |
| US-3961073-A | 2-PHENYL-CYCLOPROPYLAMINE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-06-01 | — | — | US | claimed |
| JP-55055116-A | — | — | None | — | — | JP | disclosed |
| US-3961073-A | 2-PHENYL-CYCLOPROPYLAMINE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-06-01 | — | — | US | disclosed |